Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) ("Opus Genetics” or the "Company” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback